Howard Hughes Medical Insititute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, United States.
Semin Cancer Biol. 2013 Feb;23(1):18-25. doi: 10.1016/j.semcancer.2012.06.001. Epub 2012 Jun 13.
Inactivation of the VHL tumor suppressor protein (pVHL) is a common event in clear cell renal carcinoma, which is the most common form of kidney cancer. pVHL performs many functions, including serving as the substrate recognition module of an ubiquitin ligase complex that targets the alpha subunits of the heterodimeric HIF transcription factor for proteasomal degradation. Deregulation of HIF2α appears to be a driving force in pVHL-defective clear cell renal carcinomas. In contrast, genetic and functional studies suggest that HIF1α serves as a tumor suppressor and is a likely target of the 14q deletions that are characteristic of this tumor type. Drugs that inhibit HIF2α, or its downstream targets such as VEGF, are in various stages of clinical testing. Indeed, clear cell renal carcinomas are exquisitely sensitive to VEGF deprivation and four VEGF inhibitors have now been approved for the treatment of this disease.
VHL 肿瘤抑制蛋白 (pVHL) 的失活是肾透明细胞癌的常见事件,肾透明细胞癌是最常见的肾癌形式。pVHL 具有多种功能,包括作为泛素连接酶复合物的底物识别模块,该复合物将异二聚体 HIF 转录因子的α亚基作为靶标进行蛋白酶体降解。HIF2α 的失调似乎是 pVHL 缺陷型肾透明细胞癌的驱动因素。相比之下,遗传和功能研究表明,HIF1α 作为肿瘤抑制因子,可能是 14q 缺失的靶标,14q 缺失是该肿瘤类型的特征。抑制 HIF2α 或其下游靶标(如 VEGF)的药物正在不同阶段的临床试验中。事实上,肾透明细胞癌对 VEGF 剥夺非常敏感,目前已有四种 VEGF 抑制剂被批准用于治疗这种疾病。